Xyntha FDA Approval History
FDA Approved: Yes (First approved February 21, 2008)
Brand name: Xyntha
Generic name: antihemophilic factor (recombinant), plasma/albumin free
Company: Wyeth Pharmaceuticals Inc.
Treatment for: Hemophilia A
Xyntha (Antihemophilic Factor (Recombinant) Plasma/Albumin Free) is a genetically engineered version of factor VIII, a protein essential for the clotting of blood. Xyntha is indicated for the control and prevention of bleeding episodes and for surgical prophylaxis in patients with hemophilia A.
Development timeline for Xyntha
| Date | Article |
|---|---|
| Feb 21, 2008 | Approval FDA Licenses Xyntha, a New Hemophilia Treatment |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
